Acalabrutinib–Venetoclax improves progression-free survival and reduces disease progression in untreated chronic lymphocytic ...

Leukemia is a leading cause of death among children in India, with over 30,000 cases diagnosed annually. Early diagnosis is ...

Risk factors for chronic lymphocytic leukemia (CLL) include having a family history of CLL, being over the age of 50, exposure to certain chemicals, your biological sex, and your race. Chronic ...

During the past several decades, medical and technological advancements have led to the development of chemoimmunotherapeutic agents and targeted therapies, improving survival in individuals with ...

The chronic lymphocytic leukemia (CLL) care team often takes a multidisciplinary approach, with specialists and healthcare professionals collaborating to provide a comprehensive, personalized ...

However, leukemia originates in the bone marrow and spreads through the blood, while lymphoma originates in the spleen or lymph nodes and spreads through the lymph vessels. Leukemia and lymphoma can ...

The long-term safety of ibrutinib was proven in patients with newly diagnosed or relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Quality-of ...

During a Case-Based Roundtable® event, Nakhle Saba, MD, and participants discussed treatment for a patient with chronic lymphocytic leukemia who received 1 prior line of therapy in the first article ...

An international study published in the New England Journal of Medicine provides hope for chronic lymphocytic leukemia (CLL) ...

Hope is crucial for those of us with chronic lymphocytic leukemia, or any cancer, helping us navigate the disease's ...

Introduction: A unique feature of chronic lymphocytic leukemia (CLL) is the increased number of circulating T cells preventing malignant B cells from undergoing apoptosis. Dysregulated expression of ...